



Ref: JSTL/BOD/BSE/2026-27/ AUG26

Date: August 01, 2026

To
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001.

Dear Sir/Madam,

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

Sub: Intimation of Approval for addition of Beds to the Existing Approved Bioavailability/Bioequivalence Center of Jeevan Scientific Technology Limited's Bioavailability/Bioequivalence Study Center, located at Plot No. B-17, TIE Phase II, Balanagar, Hyderabad-500037, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform the Exchange that the Central Drugs Standard Control Organization (CDSCO) has granted approval for the increase in the bed capacity from 132 and 06 ICU beds to 156 and 08 ICU beds of the Company's existing approved Bioavailability/Bioequivalence (BA/BE) Study Centre situated at Plot No. B-17, TIE Phase II, Balanagar, Hyderabad - 500037, Telangana, India.

The approval has been granted pursuant to the successful completion of the regulatory inspection conducted by the CDSCO on June 24, 2026 and the Company's application seeking enhancement of the bed capacity at the said BA/BE Study Centre.

The increased bed capacity will strengthen the Company's clinical research infrastructure, enhance its operational capabilities, and enable it to undertake a higher volume of Bioavailability/Bioequivalence studies, thereby supporting future business growth.

The Company remains committed to maintaining the highest standards of quality, regulatory compliance, and patient safety in all its clinical research operations.

This is for your information and record.

Yours faithfully,

For Jeevan Scientific Technology Limited

Krishna Sainadh Kodati
Company Secretary & Compliance Officer